GeoVax LabsGOVX
About: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Employees: 17
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
58% more capital invested
Capital invested by funds: $624K [Q2] → $985K (+$362K) [Q3]
33% more funds holding
Funds holding: 12 [Q2] → 16 (+4) [Q3]
2.94% less ownership
Funds ownership: 7.74% [Q2] → 4.79% (-2.94%) [Q3]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
D. Boral Capital Jason Kolbert 13% 1-year accuracy 11 / 87 met price target | 519%upside $18 | Buy Maintained | 19 Nov 2024 |
HC Wainwright & Co. Vernon Bernardino 36% 1-year accuracy 19 / 53 met price target | 175%upside $8 | Buy Reiterated | 15 Nov 2024 |
D. Boral Capital Jason Kolbert 13% 1-year accuracy 11 / 87 met price target | 519%upside $18 | Buy Maintained | 13 Nov 2024 |
Alliance Global Partners James Molloy 0% 1-year accuracy 0 / 10 met price target | 415%upside $15 | Buy Initiated | 11 Nov 2024 |
EF Hutton Jason Kolbert 13% 1-year accuracy 11 / 87 met price target | 519%upside $18 | Buy Maintained | 2 Oct 2024 |
Financial journalist opinion
Based on 3 articles about GOVX published over the past 30 days
